Multinational Pharma Giants Announce New Investment and Product Launch Plans at CIIE

At this year's CIIE, many multinational pharmaceutical companies that have participated in the CIIE for six consecutive years as "full-time participants" gathered. They also announced their "new product launch" plans during the CIIE.

 

AstraZeneca PLC CEO Pascal Soriot introduced that at this CIIE, AstraZeneca announced plans to invest approximately 400 million US dollars in constructing a new small molecule drug factory in Wuxi. The global R&D China Center has also been launched in Shanghai.

 

2023 marks the 30th anniversary of AstraZeneca's presence in the Chinese market. At this year's CIIE, AstraZeneca showcased nearly 40 innovative drugs introduced to China over the past 30 years. Six editions of the CIIE have served as an "accelerator" for AstraZeneca's development in China. Since 2019, AstraZeneca has established five regional headquarters in China, located in Beijing, Guangzhou, Hangzhou, Chengdu, and Qingdao, promoting the integration of the entire medical industry chain. Additionally, the company has invested in building two production bases in Wuxi and Taizhou, aiming to create globally exemplary smart factories and zero-carbon factories.

 

"This is my third visit to China this year, and I may come again before the end of the year," said Paul Hudson, CEO of Sanofi, highlighting the company’s confidence in its long-term commitment to the Chinese market and its anticipation of continued collaboration with Chinese partners.

 

In China, Sweden also adheres to "long-termism."EnterpriseElekta. Gustaf Salford, President and CEO of Elekta, introduced that the company's history in China can be traced back to 1982. After the first China International Import Expo in 2018, Elekta relocated its regional headquarters to Shanghai. Since then, Elekta has continuously accelerated its localization process in China, adding multiple production lines and achieving a leapfrog growth in factory capacity.

 

"In March this year, I came to China to further expand the company's business in China and provide more advanced global medical solutions to third- and fourth-tier markets in China."TumorTreatment solutions. Our innovation serves not only China but also the world. In the future, we will continue to accelerate innovation and sustain investment in development in China." Said Sheng Haoran.

 

According to the countryMedicineThe relevant person in charge of the Supervision and Administration Bureau introduced that in recent years, a total of 130 innovative drugs have been approved.Medical DeviceA total of 217, including 24 innovative drugs and 28 innovative medical devices, were approved for marketing in China in the first half of 2023 alone.

 

Paul Hudson emphasized that he believes China's continuous advancement in regulatory modernization can accelerate the company's development of breakthrough innovative drugs. "Especially in recent years, the mechanism for protecting intellectual property rights has been continuously strengthened, which is crucial for our long-term biotechnology..."Pharmaceuticals"Innovation is crucial."